Total amount: € 0,00
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
Online ISSN 1827-1839
Claudio CIMMINIELLO 1, Hernan POLO FRIZ 1, 2, Giuseppe MARANO 3, Guido ARPAIA 4, Patrizia BORACCHI 3, Gabriella SPEZZIGU 2, Adriana VISONÀ 5, on behalf the SIAPAV Investigators
1 Studies and Research Center of the Italian Society of Angiology and Vascular Pathology (SIAPAV), Milan, Italy; 2 Internal Medicine, Medical Department, Vimercate Hospital, Vimercate, Italy; 3 Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, University of Milan, Milan, Italy; 4 Internal Medicine, Medical Department, Carate Hospital, Carate, Italy; 5 Vascular Medicine, Castelfranco Veneto Hospital, Castelfranco Veneto, Italy
BACKGROUND: Peripheral arterial disease (PAD) usually presents with intermittent claudication (IC). The aim of the present study was to assess, in clinical practice, the pattern of use of pharmacological therapies for IC in stable PAD outpatients.
METHODS: A propensity analysis was performed using data from the IDOMENEO study, an observational prospective multicenter cohort study. The association between any pharmacological symptomatic IC therapy with different variables was investigated using generalized linear mixed models with pharmacological therapy as response variable and binomial error.
RESULTS: Study population: 213 patients, male sex 147(69.0%), age mean±SD 70.0±8.6 years. Only 36.6% was under pharmacological treatment for IC, being cilostazol the most used medication (21.6%). Univariate analysis showed a probability of a patient of being assigned to any pharmacological symptomatic IC therapy of 67.0% when ABI<0.6 and 29.8% when ABI>0.6, p=0.0048, and a propensity to avoid pharmacological treatment for patients with a high number of drugs to treat CV risk factors (probability of 55.2% for <4 drugs and 19.6% for >4 drugs, p=0.0317). Multivariate analysis confirmed a higher probability of assigning treatment for ABI<0.6 (p=0.0274), and a trend to a lower probability in patients under polypharmacy (>4 drugs: OR=0.13, p=0.0546).
CONCLUSIONS: In clinical practice, only one third of stable outpatients with IC used symptomatic pharmacological therapy for IC. We found a propensity of clinicians to assign any symptomatic pharmacological IC therapy to patients with lower values of ABI and a propensity to avoid this kind of treatment in patients under polypharmacy.